New customers for digital health startups

Biospectal, the Lausanne-based startup specializing in blood pressure (BP) monitoring, has launched its app — OptiBP — in Germany and Austria, the first app ever to meet the EU's strict CE-MDR regulations for medical devices.  Using a smartphone, users can measure their BP in just 30 seconds by placing a fingertip on the camera of their smartphone camera, a faster alternative contrary to wearing the traditional cuff. The accompanying software algorithm is based on more than two million invasive blood pressure measurements. Numerous studies were conducted and validated in several countries, with the financial support of the Bill and Melinda Gates Foundation and Grand Challenges Canada. 

"The availability of democratized, clinical-grade telemedicine solutions is the future globally, and we are proud to be well ahead of other players, including Google and Apple, who are working hard on such digital health solutions,” explains Eliott Jones, Co-Founder & CEO of Biospectal. The OptiBP app was successfully launched in Switzerland in February and is now becoming increasingly popular. Following the launch in Germany and Austria, Biospectal plans to roll out OptiBP in other key European countries and then expand globally. The company has already conducted extensive studies and validations in regions such as Africa, Asia, and the USA.

Qumea enters the Romandie
After the successful completion of the pilot phase n the palliative care department in Orbe and the orthopedic department in Saint- Loup, Établissements Hospitaliers du Nord Vaudois (eHnv) has become the first organisation in the French-speaking part of Switzerland to implement QUMEA's advanced patient monitoring system. A crucial aspect of this project is data protection.  The Solothurn-based company designs and manufactures all its components in-house, exclusively in Switzerland, thus ensuring the confidentiality and security of patient and staff information, in line with eHnv's commitment to the protection of sensitive data. As such, the startup guarantees the confidentiality and security of patient and staff information, thus meeting the hospital's legal and internal requirements for the protection of sensitive data. The system will be integrated into several rooms in our hospitals by early 2025. The introduction of this system will help to reduce the average length of stay in hospital, and thus cut costs.  

machineMD signs distribution partner 
Lausanne based startup machineMD has partnered with VON HOFF AG to distribute neos - the world’s first neurophthalmoscope, to ophthalmologists and optometrists in Switzerland. neos combines a high-tech VR headset with proprietary software. The device uses data from high-speed infrared eye tracking to generate user-friendly quantitative reports, stored securely on a cloud-based platform. According to Dominic Senn, CEO of machineMD, this partnership is poised to significantly enhance the diagnostic capabilities available to ophthalmologists across Switzerland. “Von Hoff has recognized the potential of neos for Swiss ophthalmologists and is very well networked within the community, making them the ideal distribution partner for us”, he said. “With neos, Swiss ophthalmologists and optometrists can enhance their practice with a fast, comprehensive, automated neuro-ophthalmic exam. I believe this has the potential to improve the efficiency of clinical assessments", adds Lukas Eigenmann, CEO of Von Hoff.